Metal Drugs and the Anticancer Immune Response
Open accessThe DOI matches its Crossref record; 1,300 of the 1,300 references it cites were found in a registry or an index.
Abstract
The immune system deploys a multitude of innate and adaptive mechanisms not only to ward off pathogens but also to prevent malignant transformation ("immune surveillance"). Hence, a clinically apparent tumor already reflects selection for those malignant cell clones capable of evading immune recognition ("immune evasion"). Metal drugs, besides their well-investigated cytotoxic anticancer effects, massively interact with the cancer-immune interface and can reverse important aspects of immune evasion. This topic has recently gained intense attention based on combination approaches with anticancer immunotherapy (e.g., immune checkpoint inhibitors), a strategy recently delivering first exciting results in clinical settings. This review summarizes the promising but still extremely fragmentary knowledge on the interplay of metal drugs with the fidelity of anticancer immune responses but also their role in adverse effects. It highlights that, at least in some cases, metal drugs can induce long-lasting anticancer immune responses. Important steps in this process comprise altered visibility and susceptibility of cancer cells toward innate and adaptive immunity, as well as direct impacts on immune cell populations and the tumor microenvironment. On the basis of the gathered information, we suggest initiating joint multidisciplinary programs to implement comprehensive immune analyses into strategies to develop novel and smart anticancer metal compounds.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
2 retracted
Chattopadhyay, S., Dash, S. K., Mahapatra, S. K., Tripathy, S., Ghosh, T., Das, B., Das, D., Pramanik, P., & Roy, S. (2014) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-013-1085-2 · Cited by 50
RetractedChatterjee, S., Mookerjee, A., Basu, J. M., Chakraborty, P., Ganguly, A., Adhikary, A., Mukhopadhyay, D., Ganguli, S., Banerjee, R., Ashraf, M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007048 · Cited by 46
RetractedSiegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
The capsaicin receptor: a heat-activated ion channel in the pain pathway
Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., & Julius, D. (1997) · Nature · doi:10.1038/39807 · Cited by 9,107
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Research works printed but not linked: 47
- van der Most R. G., 2005, Discovery Medicine, 5, 265
- Alberts B., 2015, Mol. Biol. Cell
- Seliger B., 1996, Exp. Hematol., 24, 1275
- Fink D., 1996, Cancer Res., 56, 4881
- Yoshikawa A., 1997, Kobe J. Med. Sci., 43, 109
- 10.1007/s00775-018- 1546-8 · doi:10.1007/s00775-018-
- Rosenberg, B. In Advances in Antimicrobial and Antineoplastic Chemotherapy, University Park Press: Baltimore, 1972; Vol. 11.
- 10.1002/(SICI)1098-2264(199704)18:4<286::AID-GCC6>3.0.CO;2-X · doi:10.1002/(sici)1098-2264(199704)18:4<286::aid-gcc6>3.0.co;2-x
- Dempsey J. L., 1985, Cancer Res., 45, 2873
- Nio Y., 2000, Anticancer Res., 20, 3293
- Qin X., 2010, Cell. Mol. Biol. (Noisy- le-grand), 56, 1366
- Kleinerman E. S., 1980, Cancer Res., 40, 3099
- Lichtenstein A. K., 1986, Cancer Res., 46, 639
- 10.1002/1097-0142(19930215)71:4<1313::AID-CNCR2820710424>3.0.CO;2-# · doi:10.1002/1097-0142(19930215)71:4<1313::aid-cncr2820710424>3.0.co;2-#
- Yamaue H., 1991, J. Clin. Lab. Immunol., 35, 165
- 10.1002/(SICI)1097-0215(19971104)73:3<416::AID-IJC17>3.0.CO;2-A · doi:10.1002/(sici)1097-0215(19971104)73:3<416::aid-ijc17>3.0.co;2-a
- Jiang J., 2006, Anticancer Res., 26, 2237
- Ujiie T., 1989, Jpn. J. Exp. Med., 59, 17
- Maeda K., 2011, Anticancer Res., 31, 4569
- Miller W. H., 2002, Cancer Res., 62, 3893
- 10.1097/CJI.0b013e3181755deb · DOI
- Kreuser E. D., 1992, Semin. Oncol., 19, 73
- Magnarin M., 2000, Anticancer Res., 20, 2939
- Nardon C., 2014, Anticancer Res., 34, 487
- Hashimoto K., 1994, J. Rheumatol., 21, 1020
- Yan A., 1990, J. Rheumatol., 17, 47
- Wang X. D., 2009, Zhongguo Shi Yan Xue Ye Xue Za Zhi, 17, 533
- 10.1371/journal.pone.0100933 · DOI · Paper page
- Korbecki J., 2012, Acta Biochim. Polym., 59, 195
- 10.3109/1547691X.2014.996681 · DOI
- Desoize B., 2004, Anticancer Res., 24, 1529
- Sava G., 1985, Anticancer Res., 5, 249
- Boscolo P., 2004, Ann. Clin. Lab. Sci., 34, 299
- Brewer G. J., 2000, Clin. Cancer Res., 6, 1
- Redman B. G., 2003, Clin. Cancer Res., 9, 1666
- Pan Q., 2003, Mol. Cancer Res., 1, 701
- Lukasewycz O. A., 1982, J. Natl. Cancer Inst., 69, 489
- 10.1515/9783110470734-016 · doi:10.1515/9783110470734-016
- Eriksson M., 2009, Anticancer Res., 29, 11
- Signat B., 2011, Curr. Issues Mol. Biol., 13, 25
- Sonis S. T., 2004, J. Support. Oncol., 2, 21
- 10.1053/sonc.2002.35524 · doi:10.1053/sonc.2002.35524 · Paper page
- Juhn S. K., 2001, Int. Tinnitus J., 7, 72
- Boussios S., 2012, Ann. Gastroenterol., 25, 106
- Takeyama K., 2000, Int. J. Hematol., 71, 144
- Giles F. J., 1994, Curr. Opin. Hematol., 1, 256
- Lu J., 2017, Ochsner J., 17, 379
Cited by
Items 201–300 of 354
Geisler, H., Harringer, S., Wenisch, D., Urban, R., Jakupec, M. A., Kandioller, W., & Keppler, B. K. (2022) · ChemistryOpen · doi:10.1002/open.202200019 · Cited by 14
Self-citationJana, A., Aher, A., Brandão, P., Bera, P., Sharda, S., Phadikar, U., Manna, S. K., Mahapatra, A. K., & Bera, P. (2021) · Dalton Transactions · doi:10.1039/d1dt02825a · Cited by 13
Li, C., Tu, L., Xu, Y., Li, M., Du, J., Stang, P. J., Sun, Y., & Sun, Y. (2024) · Angewandte Chemie · doi:10.1002/ange.202406392 · Cited by 13
Donati, C., Hashim, I. I., Pozsoni, N. B., Bourda, L., Hecke, K. V., Cazin, C. S. J., Visentin, F., Nolan, S. P., Gandin, V., & Scattolin, T. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00039d · Cited by 14
The Role of Ruthenium Compounds in Neurologic Diseases: A Minireview
Justi, F. V. G., Matos, G. A., Caminha, J. D. S. R., Roque, C. R., Carvalho, E. M., Campelo, M. W. S., Belayev, L., Lopes, L. G. D. F., & Oriá, R. B. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000798 · Cited by 13
“…been utilized historically in clinical medicine, and over the past five decades, they have attracted the pharmaceutical industry's attention in the relentless search for new therapeutic approaches against cancer and neurological diseases (Pricker, 1996)(Thota et al., 2018)(Englinger et al., 2019).”
BackgroundFahmy, H. M., Abdel-Rahman, F. M., Elsayed, A. A., & El-Sherif, A. A. (2023) · BMC Chemistry · doi:10.1186/s13065-023-00996-1 · Cited by 12
Li, Z., Liu, X.-M., Tan, F., Wang, J.-Q., Qiao, X., Feng, Y., Xu, J., & Hao, J.-H. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02116 · Cited by 13
Rhodium-based metallodrugs for biological applications: current status and future perspectives
Wang, X., He, S., Kuang, T., Yin, J., Hu, B., Sun, C., He, J., Wang, J., Yu, C., & Wei, H. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101941 · Cited by 12
“Metal-lodrugs exhibit immunomodulatory effects in addition to their cytotoxic anticancer effects, enabling them to reverse the evasion of immune surveillance by tumor cells and elicit durable anticancer immune responses under specific conditions [128,129].”
Wang, M., Liu, Z., Huang, X., Chen, Y., Wang, Y., Kong, J., Yang, Y., Yu, C., Li, J., Wang, X., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104741 · Cited by 12
Gulzar, S., Ammara, U., Abid, Z., Shahid, M., Ashraf, R. S., Baig, N., Kawde, A.-N. M., Bhatia, G., Isab, A. A., & Altaf, M. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.132482 · Cited by 12
Subcellular Duplex DNA and G‐Quadruplex Interaction Profiling of a Hexagonal PtII Metallacycle
Domarco, O., Kieler, C., Pirker, C., Dinhof, C., Englinger, B., Reisecker, J. M., Timelthaler, G., García, M. D., Peinador, C., Keppler, B. K., et al. (2019) · Angewandte Chemie · doi:10.1002/ange.201900934 · Cited by 12
Self-citationVa, K., Aleksanyan, D. V., Churusova, S. G., Spiridonov, A. A., Rybalkina, E. Y., Gutsul, E. I., Aksenova, S. A., Korlyukov, A. A., Peregudov, А. S., & Klemenkova, Z. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417331 · Cited by 11
Metal-based approaches to fight cervical cancer
Pereira, D., Alves, N. M., Sousa, Â., & Valente, J. F. A. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104073 · Cited by 12
Lewandowski, E. M., Szczupak, Ł., Kowalczyk, A., Mendoza, G., Arruebo, M., Jacobs, L. M. C., Stączek, P., Chen, Y., & Kowalski, K. (2020) · ChemBioChem · doi:10.1002/cbic.202000054 · Cited by 11
Kesharwani, K., Singh, R. S., Khan, M. J., Vinayak, V., & Joshi, K. B. (2021) · ChemistrySelect · doi:10.1002/slct.202102204 · Cited by 11
Dinev, D., Popova, K. B., Zhivkova, T., Dyakova, L., Abudalleh, A., Alexandrova, R., Culita, D. C., Mocanu, T., Maxim, C., & Marinescu, G. (2022) · Applied Organometallic Chemistry · doi:10.1002/aoc.6862 · Cited by 11
Nature of NMR Shifts in Paramagnetic Octahedral Ru(III) Complexes with Axial Pyridine-Based Ligands
Chyba, J., Hruzíková, A., Knor, M., Pikulová, P., Marková, K., Novotný, J., & Marek, R. (2023) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.2c03282 · Cited by 13
Bhattacharyya, A., Jameei, A., Saha, R., Garai, A., Karande, A. A., & Chakravarty, A. R. (2020) · Dalton Transactions · doi:10.1039/d0dt03342a · Cited by 11
Gil‐García, R., Madariaga, G., Jiménez-Pérez, A., Herrán-Torres, I., Gago-González, A., Ugalde, M., Januskaitis, V., Barrera-García, J., Insausti, M., Galletero, M. S., et al. (2023) · CrystEngComm · doi:10.1039/d3ce00119a · Cited by 10
Yu, X., Zhou, Y., Ma, X., Zhang, W., Li, F., Jiang, F., Wang, Y., Zhang, Q., & Liu, W. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01354 · Cited by 13
Ren, M., Sun, X., Lin, J., Kan, Y., Lu, S., Zhang, X.-K., Liang, R., Wang, B., Chen, H., Wu, Y., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113717 · Cited by 13
Chopra, D., Zhang, L., Guo, T., Ivanovski, S., Qiao, R., & Gulati, K. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202510739 · Cited by 10
Petrović, B., Jovanović, S., Puchta, R., & van Eldik, R. (2019) · Inorganica Chimica Acta · doi:10.1016/j.ica.2019.06.004 · Cited by 10
Shu, J., Yue, J., Qiu, X., Liu, X., Wang, R., Li, Q., Li, Y., Xu, B., Zhang, K., & Jiang, W. (2021) · Inorganic Chemistry Frontiers · doi:10.1039/d1qi00108f · Cited by 10
Mikhnavets, L., Abashkin, V., Khamitsevich, H., Shcharbin, D., Burko, A., Krekoten, N., & Radziuk, D. V. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c01603 · Cited by 11
Hu, G., Lv, M., Guo, B., Huang, Y., Su, Z. G., Qian, Y., Xue, X., & Liu, H. (2023) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2023.112195 · Cited by 10
Yan, J., Chen, S., Lou, K., Gu, M., Wang, X., Pan, D., Wang, L., Xu, Y., Chen, C., Chen, Y., et al. (2023) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2023.131285 · Cited by 10
Recent Progress in Ferroptosis Induced Tumor Cell Death by Anti‐tumor Metallic complexes
Zhou, Y., Zhao, T., Tao, S., Wang, P., Guan, Y., Yang, K., Chen, S., & Pu, X. (2023) · Chemistry - An Asian Journal · doi:10.1002/asia.202301020 · Cited by 11
Liu, S., Wang, L., Zhao, B., Wang, Z., Wang, Y., Sun, B., & Liu, Y. (2020) · RSC Advances · doi:10.1039/d0ra03069d · Cited by 10
Machado, J. F., & Morais, T. S. (2022) · Dalton Transactions · doi:10.1039/d1dt04079k · Cited by 10
Levina, A., Vieira, A. P., Wijetunga, A. R., Kaur, R., Koehn, J. T., Crans, D. C., & Lay, P. A. (2020) · Angewandte Chemie · doi:10.1002/ange.202005458 · Cited by 10
Ling, Y., Xia, X., Liang, H., Wang, W., Zhang, H., Liu, L., Liu, W., Li, Z., Tan, C., & Mao, Z. (2022) · Angewandte Chemie · doi:10.1002/ange.202210988 · Cited by 10
First-in-class metallo-PROTAC as an effective degrader of select Pt-binding proteins
O'Dowd, P., Sullivan, G. P., Rodrigues, D. A., Chonghaile, T. N., & Griffith, D. M. (2023) · Chemical Communications · doi:10.1039/d3cc03340f · Cited by 10
Wong, C. H., Khor, B., Murugaiyah, V., Chear, N. J., & Yam, W. (2025) · Drug Development Research · doi:10.1002/ddr.70100 · Cited by 9
“Progress in metal ‐ based drug discovery has prompted bioinorganic chemists to design and develop a wide range of metal ‐ containing compounds with complex structures (Paprocka et al. 2022; Adhikari et al. 2024; Singh et al. 2023; Abdolmaleki et al. 2023; Englinger et al. 2019).”
Wang, X., Tang, Y., & Li, Q. (2026) · Chemical Society Reviews · doi:10.1039/d5cs01352f · Cited by 9
Sarpong‐Kumankomah, S., Contel, M., & Gailer, J. (2020) · Journal of Chromatography B · doi:10.1016/j.jchromb.2020.122093 · Cited by 9
Franich, A. A., Đorđević, I., Živković, M. D., Rajković, S., Janjić, G. V., & Djuran, M. I. (2021) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-021-01911-6 · Cited by 9
Yadhukrishnan, V. O., Muralisankar, M., Dheepika, R., Konakanchi, R., Bhuvanesh, N. S. P., & Nagarajan, S. (2020) · Journal of Coordination Chemistry · doi:10.1080/00958972.2020.1782895 · Cited by 9
Liu, L., Chen, J., Wang, M., Huang, Y., Qian, Y., Xue, X., Su, Z. G., & Liu, H. (2022) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2022.111913 · Cited by 10
Unconventional Anticancer Metallodrugs and Strategies to Improve Their Pharmacological Profile
Contel, M. (2019) · Inorganics · doi:10.3390/inorganics7070088 · Cited by 9
Nicola, C. D., Marchetti, F., Pettinari, R., Tombesi, A., Pettinari, C., Grappasonni, I., Dyson, P. J., & Scuri, S. (2020) · Materials · doi:10.3390/ma13030526 · Cited by 9
Cisplatin binds to the MDM2 RING finger domain and inhibits the ubiquitination activity
Cao, K., Ding, X., Sheng, Y., Wang, Y., & Liu, Y. (2020) · Chemical Communications · doi:10.1039/d0cc00203h · Cited by 9
Zhang, Y., Ma, Z., Qiao, P., Gao, C., Tian, J., Zhao, J., Du, W., Xu, J., & Yan, S. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130278 · Cited by 9
Feng, T., Tang, Z., Shu, J., Wu, X., Jiang, H., Chen, Z., Chen, Y., Ji, L., & Chao, H. (2024) · Angewandte Chemie · doi:10.1002/ange.202405679 · Cited by 8
Malali, S., Chyba, J., Knor, M., Horní, M., Nečas, M., Novotný, J., & Marek, R. (2020) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.0c01328 · Cited by 9
Sharma, H., Singh, V., Tamrakar, A., Nigam, K. K., Pandey, M. D., Tiwari, K. K., & Pandey, R. (2022) · Luminescence · doi:10.1002/bio.4243 · Cited by 8
Bao, Y., Ge, X., Li, L., He, J., Huang, S., Luo, X., Chen, X., Chen, P., & Yang, X. (2021) · BioMetals · doi:10.1007/s10534-021-00336-7 · Cited by 9
Gufler, J., Heffeter, P., Kowol, C. R., Hager, S., & Marko, D. (2024) · Toxicology · doi:10.1016/j.tox.2024.154039 · Cited by 7
Self-citationDijkstra, M., Schueffl, H. H., Adamova, B., Baumfried, O., Kastner, A., Berger, W., Keppler, B. K., Heffeter, P., & Kowol, C. R. (2025) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.4c05269 · Cited by 8
“58 Of note, CT26 allografts are only moderately responsive to oxaliplatin and highly carboplatin-resistant (Figure S11).”
Self-citationDetermination of Relative Stabilities of Metal‐Peptide Bonds in the Gas Phase
Cziferszky, M., Truong, D., Hartinger, C. G., & Gust, R. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202102385 · Cited by 7
Advancement in schiff base complexes for treatment of colon cancer
Kadhum, A. M., Mallah, S. H., Waheeb, A. S., Salman, A. W., Zafar, A., Ahmad, N. S., Siraj, S., & Iqbal, M. A. (2024) · Reviews in Inorganic Chemistry · doi:10.1515/revic-2024-0068 · Cited by 7
Goudarzi, A., Ghassemzadeh, M., Saeidifar, M., Aghapoor, K., Mohsenzadeh, F., & Neumüller, B. (2022) · New Journal of Chemistry · doi:10.1039/d1nj05545c · Cited by 7
Cheng, X., Wang, N., Jiang, Z., Chen, Z., Niu, Y., Tong, L., Yu, T., & Tang, B. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00080 · Cited by 7
Synthesis of Platinum(II) N-Heterocyclic Carbenes Based on Adenosine
Leitão, M. I. P. S., Francescato, G., Gomes, C. S. B., & Petronilho, A. (2021) · Molecules · doi:10.3390/molecules26175384 · Cited by 7
Platinum Twin and Triplet Drugs Improve Chemoimmunotherapy
Hao, Y., Li, R., Pan, W., Tian, S., & Min, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00792 · Cited by 6
Xie, K. M., Lu, X.-Y., Zhu, H., Zhu, L.-Y., Li, R., & Ye, R. (2024) · Dalton Transactions · doi:10.1039/d4dt00575a · Cited by 6
Paderni, D., Macedi, E., Sordini, E., Amatori, S., Rossi, P., Formica, M., Giorgi, L., Paoli, P., Fanelli, M., & Fusi, V. (2024) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2024.112758 · Cited by 6
Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy
Shirbhate, E., Singh, V. P., Kore, R., Koch, B., Veerasamy, R., Tiwari, A. K., & Rajak, H. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2458156 · Cited by 8
“Apart from solid interaction of platinum drugs with DNA to initiate DNA damage and cellular death, one cannot hide the evidences favoring immune system modulation making an essential contribution to the anticancer effectiveness of platinum compounds [75–77].”
Stimuli‐Responsive Metal Complexes for Biomedical Applications
Amarsy, I., Papot, S., & Gasser, G. (2022) · Angewandte Chemie · doi:10.1002/ange.202205900 · Cited by 7
Flipping hosts in hyperfine fields of paramagnetic guests
Novotný, J., Chyba, J., Hruzíková, A., Pikulová, P., Kursit, A., Knor, M., Marková, K., Marek, J., Jurček, P., Jurček, O., et al. (2023) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2023.101461 · Cited by 6
de Azevedo-França, J. A., Ramos, V. F. D. S., Luigi Messori, A., Santanni, F., Sorace, L., Borba-Santos, L. P., Rozental, S., Rodrigues, J. C. F., & Navarro, M. (2023) · New Journal of Chemistry · doi:10.1039/d3nj04608g · Cited by 6
Śpiewak, K., Świątek, S., Jachimska, B., & Brindell, M. (2019) · New Journal of Chemistry · doi:10.1039/c9nj01342c · Cited by 6
Liu, J., & Cao, C. (2020) · The Analyst · doi:10.1039/d0an00627k · Cited by 6
Hinton, S. R., Corpuz, E. L. S., Holman, K. L. M., & Meyer, S. C. (2022) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2022.111986 · Cited by 6
Ferrocenyl ferroptosis inducers as an emerging class of anticancer agents: a mini review
Klarek, M., Gautam, A., & Kowalski, K. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md00935a · Cited by 5
An NIR-II-emissive Ru(II) metallacycle for efficient and safe immunotherapy
Li, C., Zhan, J., & Dong, B. (2024) · Science China Chemistry · doi:10.1007/s11426-024-2193-5 · Cited by 5
Kastner, A., Poetsch, I., Mayr, J., Burda, J. V., Roller, A., Heffeter, P., Keppler, B. K., & Kowol, C. R. (2019) · Angewandte Chemie · doi:10.1002/ange.201900682 · Cited by 5
Self-citationPharmacophore conjugation strategy for multi-targeting metal-based anticancer complexes
Zhao, Y., Kang, Y., Xu, F., Zheng, W., Luo, Q., Zhang, Y., Jia, F., & Wang, F. (2019) · Advances in inorganic chemistry · doi:10.1016/bs.adioch.2019.10.002 · Cited by 5
Chen, X., Ding, Q., Lin, T., Sun, Y., Huang, Z., Li, Y., Hong, W., Chen, X., Wang, D., & Qiu, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1109503 · Cited by 6
“Immunotherapy drugs targeting PD-L1 and CTLA-4 are playing an increasingly critical role in the treatment of malignant tumors (46).”
BackgroundYang, J., Wang, M., Deng, D., Lin, H. L., Su, Y. R., Shao, C.-X., Li, S., Yu, Z., Liu, H., & Su, Z. G. (2024) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.4c00321 · Cited by 5
Sumithaa, C., Sugantharam, K., Karanath‐Anilkumar, A., Munuswamy‐Ramanujam, G., & Ganeshpandian, M. (2024) · Chemical Communications · doi:10.1039/d4cc03368j · Cited by 7
Das, P., Roy, S., Das, C., Biswas, R., Chaterjee, N., & Dinda, J. (2024) · New Journal of Chemistry · doi:10.1039/d4nj02853h · Cited by 5
Chen, C., Zheng, Y., Rao, H., Huang, F., Shen, C., & Lu, C. (2024) · Applied Organometallic Chemistry · doi:10.1002/aoc.7756 · Cited by 5
Metallocomplex–Peptide Interactions Studied by Ultrahigh Resolution Mass Spectrometry
Chiu, C. K. C., Lam, Y. P. Y., Wootton, C. A., Barrow, M. P., Sadler, P. J., & O’Connor, P. B. (2020) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.9b00054 · Cited by 5
Zhang, Y., Ma, Z., Qiao, P., Gao, C., Tian, J., Zhao, J., Du, W., Xu, J., & Yan, S. (2020) · Polyhedron · doi:10.1016/j.poly.2020.114880 · Cited by 6
Şahal, H., Öz, S., Keskin, T., Tekin, S., Canpolat, E., & Kaya, M. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2192803 · Cited by 5
“In addition, transition metal complexes are known to have been used as anticancer agents for decades (Englinger et al., 2019).”
BackgroundGrand challenges in bioinorganic chemistry
Correia, I., & Draper, S. M. (2023) · Frontiers in Chemical Biology · doi:10.3389/fchbi.2023.1165773 · Cited by 4
“, 2023) and anticancer immunotherapy (Englinger et al., 2019), are at the forefront of modern cancer therapeutics.”
BackgroundCaban, M., Fronik, P., Terenzi, A., Federa, A., Nunes, J. H. B., Pitek, R., Kirchhofer, D., Schueffl, H. H., Berger, W., Keppler, B. K., et al. (2025) · Inorganic Chemistry Frontiers · doi:10.1039/d4qi03025g · Cited by 6
Self-citationPruchnik, H., Solarska‐Ściuk, K., Dudek, A., & Włoch, A. (2025) · Molecules · doi:10.3390/molecules30030476 · Cited by 4
Cyclometalated iridium(III)-lonidamine conjugates: Mitochondrial targeting and pyroptosis induction
Lu, X.-Y., Zhu, L.-Y., Zhu, H., Huang, S., Yang, Y., Jiang, C.-R., & Ye, R. (2025) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2025.112852 · Cited by 4
Xu, Z., Yang, Z., Lv, L., Yang, J., & Liu, W. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00026 · Cited by 6
A Comprehensive Review for Ruthenium(II) Complexes in Photodynamic Therapy
Mukherjee, R. (2023) · Asian Journal of Chemistry · doi:10.14233/ajchem.2023.28555 · Cited by 4
Yu, Z., Guo, S., Wang, B.-S., Ouyang, S., Zhang, X., Zhao, Z., & Wang, J. (2024) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/0115748928320508240802055846 · Cited by 4
Ruthenium(II) Complexes as Potential Apoptosis Inducers in Cancer Therapy
Zarić, R. Ž., Pirković, M. S., & Hamzagić, N. (2019) · EABR. Experimental and Applied Biomedical Research · doi:10.2478/sjecr-2019-0016 · Cited by 4
Necroptosis Induced by Ruthenium(II) Complexes as Dual Catalytic Inhibitors of Topoisomerase I/II
Xiong, K., Qian, C., Yuan, Y., Wei, L., Liao, X., He, L., Rees, T. W., Chen, Y., Wan, J., Ji, L., et al. (2020) · Angewandte Chemie · doi:10.1002/ange.202006089 · Cited by 4
A combined solid state, solution and DFT study of a dimethyl-cyclen-Pd( ii ) complex
Paderni, D., Voccia, M., Macedi, E., Formica, M., Giorgi, L., Caporaso, L., & Fusi, V. (2024) · Dalton Transactions · doi:10.1039/d4dt01791a · Cited by 4
Organometallic conjugates of artesunate: synthesis and evaluation of anticancer potential
van der Merwe, L., Kaschula, C. H., & Chellan, P. (2025) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2025.123804 · Cited by 3
Progress and prospects of metal-based immunotherapy in breast cancer
Liang, J., Yang, X., & Zhang, Y. (2025) · BioMetals · doi:10.1007/s10534-025-00747-w · Cited by 3
“Under the combined effect of photothermal therapy (PTT) and CDT, tumor cells undergo death, releasing antigens, inducing ICD, and activating cytotoxic T cells The combination of metal complexes and chemotherapy drugs can synergistically enhance anti-tumor effects.”
InfluentialBiological insights into BODIPY and porphyrin‐functionalized fluorescent metal–organic macrocycles
Gupta, G., Das, A. K., & Lee, C. Y. (2025) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.70072 · Cited by 3
Pessoa, J. C., Zarroug, R., Ribeiro, N., Correia, I., Côrte‐Real, L., Ayed, B., Gomes, C. S. B., Marques, F., Masip‐Sánchez, A., Hernández-Carrasco, M., et al. (2025) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.5c03076 · Cited by 3
Shee, M., Deepak, K., Chatterjee, S., Mandal, M., & Singh, N. D. P. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01855b · Cited by 3
Sharkawy, S., Acharya, S., Kostrhunová, H., Maji, M., Marková, L., Novohradský, V., Gibson, D., & Brabec, V. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01858 · Cited by 3
Pattanayak, P. D., Patra, S. A., Das, S., Mohapatra, D., Lima, S., Sanna, D., Pisanu, F., Garribba, E., & Dinda, R. (2026) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.5c04486 · Cited by 3
Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy
Gutmann, M., Dijkstra, M., Salomon, P., Cowles, J., Federa, A., Baier, D., Jaunecker, C., Semerean, I., Karvonen, V., Pirker, C., et al. (2026) · Advanced Science · doi:10.1002/advs.202514588 · Cited by 3
“Among the worldwide approved platinum(II) drugs, oxaliplatin is of particular interest for combination with immunomodulatory drugs, like TLR agonists, as it is considered a bona fide inducer of immunogenic cell death (ICD) [ 28, 29 ].”
Self-citationBidentate Metal-Binding Motifs in US FDA Approved Small Molecule Drugs
Njardarson, J. T., & Tomat, E. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01319 · Cited by 3
Gosavi-Mirkute, P., Salunke‐Gawali, S., Lande, D. N., Gejji, S. P., Ashtekar, H., Jadhav, M. S., & Butcher, R. J. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.141512 · Cited by 3
Gold Acyclic Diaminocarbene Complexes as Selective and Potent Agents for Multitarget Cancer Therapy
Gil‐Moles, M., Aliaga‐Lavrijsen, M., Montanel‐Pérez, S., Marzo, I., Villacampa, M. D., & Gimeno, M. C. (2025) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.5c00579 · Cited by 6
Thong, P. V., Meervelt, L. V., & Thanh, N. T. (2022) · Polyhedron · doi:10.1016/j.poly.2022.116180 · Cited by 3
Suganya, M., & Puthilibai, G. (2024) · Asian Journal of Chemistry · doi:10.14233/ajchem.2024.30955 · Cited by 3
Linh, N. T. B., Ninh, N. H., Thong, P. V., Dung, T. N., Dương, N. T., Duyên, L. T., Trang, N. T. Q., Hải, L. T. H., & Thanh, N. T. (2024) · Polyhedron · doi:10.1016/j.poly.2024.117117 · Cited by 3
Metadata
- Authors
- Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W.
- Affiliations
- Comprehensive Cancer Center Vienna (AT)
- University of Vienna (AT)
- Corresponding author
- Berger, Walter
- ORCID
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-11-29
- Volume
- 119
- Issue
- 2
- Pages
- 1519-1624
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2903051221
- Cited by
- 355
- References
- 1,298
- Citations by year
- 2026: 28 · 2025: 44 · 2024: 47 · 2023: 51 · 2022: 49 · 2021: 45 · 2020: 53 · 2019: 38
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Chemical Reviews (publishedVersion)
- PubMed (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Funders
- FP7 People: Marie-Curie Actions (609431)
- Universit?t Wien
- Medizinische Universit?t Wien
- Johanna Mahlke, geb. Obermann-Stiftung zur F?rderung der Krebsforschung an der Universit?t Wien
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- metal-based anticancer agents, antitumor immunity, immune surveillance, immune evasion, cancer immunotherapy, immune checkpoint inhibitors, tumor microenvironment, innate and adaptive immunity
- MeSH terms
- Gastrointestinal Microbiome, Antineoplastic Agents, Humans, Immunity, Innate, Immunotherapy, Lymphocytes, Metals, Neoplasms, Nanoparticles, Coordination Complexes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.